Inhibrx Biosciences Inc. (INBX) vs Maze Therapeutics, Inc. (MAZE)
A side-by-side comparison of Inhibrx Biosciences Inc. and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INBX
Inhibrx Biosciences Inc.
$95.99HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT
MAZE
Maze Therapeutics, Inc.
$26.47HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — INBX vs MAZE
growth of $100 · dividends reinvested · last 2yINBX +597.9% (+164.2%/yr)MAZE +65.7% (+28.7%/yr)INBX compounded faster over this window
INBX MAZE
INBX vs MAZE: by the numbers
- •MAZE is the larger company ($1.46B vs $1.41B market cap).
- •Both run net losses; MAZE's is the smaller (-667.95% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | INBX | MAZE |
|---|---|---|
| P/S ratio | N/A | 73.25 |
| P/B ratio | N/A | 3.23 |
Profitability
| Metric | INBX | MAZE |
|---|---|---|
| Gross margin | -91.00% | 0.00% |
| Operating margin | -10386.54% | 0.00% |
| Net margin | -10773.46% | -667.95% |
| ROE | N/A | -29.48% |
| ROIC | -99.35% | -28.63% |
Growth (annualized)
| Metric | INBX | MAZE |
|---|---|---|
| Total return CAGR (5Y) | 27.64% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.